Mismatch repair deficiency predicts response of solid tumors to PD-1 blockadeDung T. Le, Luis A. Díaz, Tim F. Greten et al.|Science|2017Cited by 6.6k
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Andrea Cercek, Salvatore Siena et al.|The Lancet Oncology|2023Cited by 244
Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion CholangiocarcinomaMelanie A. Krook, Sameek Roychowdhury, Alexandria Lenyo et al.|Molecular Cancer Therapeutics|2020Cited by 138
NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.T.R. Jeffry Evans, Jordan Berlin, Sarah P. Blagden et al.|Journal of Clinical Oncology|2019Cited by 7
A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).Andrew L. Coveler, T.R. Jeffry Evans, Farasat Kazmi et al.|Journal of Clinical Oncology|2021Cited by 6